Pharmaceutical Information |
Drug Name |
Bendamustine |
Drug ID |
BADD_D00230 |
Description |
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown. |
Indications and Usage |
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. |
Marketing Status |
Prescription |
ATC Code |
L01AA09 |
DrugBank ID |
DB06769
|
KEGG ID |
D07501
|
MeSH ID |
D000069461
|
PubChem ID |
65628
|
TTD Drug ID |
D01CYA
|
NDC Product Code |
68554-0050 |
Synonyms |
Bendamustine Hydrochloride | Hydrochloride, Bendamustine | Bendamustine | Bendamustin | Cytostasan | IMET 3393 | Ribomustin | Treanda | Zimet 3393 |
|
Chemical Information |
Molecular Formula |
C16H21Cl2N3O2 |
CAS Registry Number |
16506-27-7 |
SMILES |
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
|